News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

In Connection With Kos Pharmaceuticals (KOSP) Strategic Alliance With {3}, Christopher Kiritsy To Become President And CEO Of Triad


10/19/2005 5:12:39 PM

CRANBURY, N.J.--(BUSINESS WIRE)--Feb. 7, 2005--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP): -- Kos announces the pending resignation of Kiritsy as EVP and CFO of Kos -- Pending Kiritsy resignation to become effective when successor CFO is found -- Adrian Adams also appointed as Chairman of Triad as part of Kos Board representation Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that Christopher P. Kiritsy, Kos' Executive Vice President and Chief Financial Officer, will resign his position at Kos in order to become President and CEO of Triad Pharmaceuticals, Inc. ("Triad"), a company in which Kos has recently made a strategic investment (which is the subject of a separate press release issued today). In connection with Kos' investment in Triad, Adrian Adams, Kos' President and Chief Executive Officer, will also assume the role of Chairman of the Board of Directors of Triad in addition to his continuing role as President and CEO of Kos. Triad, located in Boston, MA, is a privately held drug discovery and design pharmaceutical company focused on developing highly potent and selective small molecules for a variety of diseases, including treatments for diabetes, cancer and cholesterol disorders.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES